Frankfurt - Delayed Quote EUR

Prothena Corporation plc (0PT.F)

4.5200
-0.0200
(-0.44%)
As of 9:07:20 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
137,935
135,157
91,370
53,905
200,577
Operating Expense
276,549
289,718
282,406
185,462
128,602
Operating Income
-138,614
-154,561
-191,036
-131,557
71,975
Net Non Operating Interest Income Expense
22,999
25,816
31,014
6,349
42
Other Income Expense
-248
-185
-458
-397
-96
Pretax Income
-115,863
-128,930
-160,480
-125,605
71,921
Tax Provision
-5,597
-6,620
-13,452
-8,656
4,946
Net Income Common Stockholders
-110,266
-122,310
-147,028
-116,949
66,975
Diluted NI Available to Com Stockholders
-110,266
-122,310
-147,028
-116,949
66,975
Basic EPS
-2.05
--
-2.76
-2.47
1.51
Diluted EPS
-2.05
--
-2.76
-2.47
1.38
Basic Average Shares
53,800.2500
--
53,216
47,369
44,228
Diluted Average Shares
53,800.2500
--
53,216
47,369
48,464
Total Operating Income as Reported
-138,614
-154,561
-191,036
-131,557
71,975
Total Expenses
276,549
289,718
282,406
185,462
128,602
Net Income from Continuing & Discontinued Operation
-110,266
-122,310
-147,028
-116,949
66,975
Normalized Income
-110,089.9368
-122,134.4990
-146,608.3912
-116,579.3590
66,975
Interest Income
22,999
25,816
31,014
6,349
42
Interest Expense
0
--
--
--
--
Net Interest Income
22,999
25,816
31,014
6,349
42
EBIT
-138,614
-154,561
-191,036
-131,557
71,975
EBITDA
-137,713
-153,668
-190,108
-130,813
73,090
Reconciled Depreciation
901
893
928
744
1,115
Net Income from Continuing Operation Net Minority Interest
-110,266
-122,310
-147,028
-116,949
66,975
Total Unusual Items Excluding Goodwill
-185
-185
-458
-397
0
Total Unusual Items
-185
-185
-458
-397
0
Normalized EBITDA
-137,528
-153,483
-189,650
-130,416
73,090
Tax Rate for Calcs
0
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-8.9368
-9.4990
-38.3912
-27.3590
0
12/31/2021 - 1/11/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IDD.F Innate Pharma S.A.
1.8720
-0.21%
 
FYB.SG Formycon AG
28.80
+5.69%
 
IPHYF Innate Pharma S.A.
1.4500
0.00%
 
5NRA.MU Nanobiotix SA
4.0800
+1.49%
 
9VC.F Atai Life Sciences N.V.
2.0690
-2.50%
 
ALCLS.PA Cellectis S.A.
1.2880
0.00%
 
FYB.F Formycon AG
27.10
-0.55%
 
RGO.SG Regeneron Pharmaceuticals Inc
434.90
-0.41%
 
GNLX Genelux Corporation
2.5600
+1.19%
 
LXEO Lexeo Therapeutics, Inc.
3.8800
+18.65%